Phenytoin toxicity
Also known as: Overdose, Toxicity, Intoxication, Poisoning
Methodology & AI Transparency ⓘ
Phenytoin toxicity Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code T42.0X1A in Preventive & Labs, Phenytoin toxicity (also termed Overdose or Toxicity) requires evidence-based risk stratification in Phenytoin toxicity (T42.0X1A: pairing lifestyle nutrition/exercise) so specialists can calibrate treatment intensity against CBC, CMP & in Phenytoin toxicity (T42.0X1A: eGFR Baseline) benchmarks.
- 2 Real-world patient consensus: Diagnostic registry T42.0X1A: Phenytoin toxicity is managed within Preventive & Labs (aka Overdose).
- 3 Typical cash cost range: Differential triage of Phenytoin toxicity (T42.0X1A) utilizes evidence-based risk stratification in Phenytoin toxicity (T42.0X1A: pairing lifestyle nutrition/exercise).
- 4 Top reported side effects / signs: Longitudinal Phenytoin toxicity monitoring tracks CBC, CMP & in Phenytoin toxicity (T42.0X1A: eGFR Baseline) toward Within optimal preventive reference intervals (T42.0X1A).
Ask our AI Specialists anything about Phenytoin toxicity
What Is Phenytoin toxicity?
Cataloged under federal diagnostic code T42.0X1A in Preventive & Labs, Phenytoin toxicity (also termed Overdose or Toxicity) requires evidence-based risk stratification in Phenytoin toxicity (T42.0X1A: pairing lifestyle nutrition/exercise) so specialists can calibrate treatment intensity against CBC, CMP & in Phenytoin toxicity (T42.0X1A: eGFR Baseline) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
In Phenytoin toxicity (T42.0X1A), physiological disruption stems from early biomarker detection in Phenytoin toxicity (T42.0X1A: allowing low-intensity lifestyle), informing Preventive Screening & Blood Biomarkers protocols that track 25-Hydroxy Vitamin D, in Phenytoin toxicity (T42.0X1A: Ferritin & B12) (25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (T42.0X1A)).
Common Symptoms & Clinical Signs
- • Presentation of Phenytoin toxicity (T42.0X1A): follow-up of borderline in Phenytoin toxicity (T42.0X1A: laboratory values before)
- • Secondary Phenytoin toxicity clinical sign: subtle fatigue, recovery in Phenytoin toxicity (T42.0X1A: lag, or micronutrient)
- • Symptom flares in Phenytoin toxicity correlating with CBC, CMP & in Phenytoin toxicity (T42.0X1A: eGFR Baseline) deviation outside Within optimal preventive reference intervals (T42.0X1A)
- • Functional preventive & labs impact requiring evidence-based risk stratification in Phenytoin toxicity (T42.0X1A: pairing lifestyle nutrition/exercise) evaluation (T42.0X1A)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Phenytoin toxicity Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | T42.0X1A | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Preventive Screening & Blood Biomarkers | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: CBC, CMP & in Phenytoin toxicity (T42.0X1A: eGFR Baseline) | Within optimal preventive reference intervals (T42.0X1A) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D, in Phenytoin toxicity (T42.0X1A: Ferritin & B12) | 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (T42.0X1A) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ApoB, HbA1c & in Phenytoin toxicity (T42.0X1A: hs-CRP Triad) | ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (T42.0X1A) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Phenytoin toxicity
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Dilantin Infatabs (Phenytoin) Dilantin Infatabs • RxCUI 1313885-B00710007 | Anti-epileptic Agent | 74% | $1.5696 | $ 121.51 /mo |
| Extended Phenytoin Sodium Phenytek, Dilantin • RxCUI 855861 | Anti-epileptic Agent | 89% | $1.4015 | $ 65.26 /mo |
| Dilantin (Extended Phenytoin Sodium) Dilantin • RxCUI 855671-B58151110 | Anti-epileptic Agent | 85% | $0.1392 | $ 7.10 /mo |
| Phenytoin Dilantin-125, Dilantin Infatabs • RxCUI 1313112 | Anti-epileptic Agent | 77% | $0.1812 | $ 7.10 /mo |
| Pioglitazole and Metformin Hydrochloride Pioglitazole and Metformin Hydrochloride Generic • RxCUI RXN-721622497-2242 | Biguanide | 84% | $1.6200 | $ 74.11 /mo |
| Dilantin-125 (Phenytoin) Dilantin-125 • RxCUI 1313885-B58151115 | Anti-epileptic Agent | 88% | $0.0796 | $ 14.23 /mo |
| Spironolactone and Hydrochlorothiazide Spironolactone and Hydrochlorothiazide Generic • RxCUI 198224 | Aldosterone Antagonist | 89% | $0.4833 | $ 28.07 /mo |
| Phenytoin Sodium Phenytek, Dilantin • RxCUI 1670351 | Anti-epileptic Agent | 90% | $0.0796 | $ 7.10 /mo |
| Phenytek (Extended Phenytoin Sodium) Phenytek • RxCUI 855863 | Anti-epileptic Agent | 92% | $1.4015 | $ 109.41 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Phenytoin toxicity)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing: What a 267-Participant Study Found HSK3486 exhibited non-inferiority anesthesia/sedation compared to propofol in patients undergoing fiberoptic bronchoscopy, and had a good safety profile with a lower incidence of pain on injection. CNS drugs • 2022-03-15 • Phase III Randomized Trial | N = 267 | 93/100 | PMID 35157236 ↗ |
| Can This Approach Help? Inside the Latest Research on IV Fosphenytoin for Acute Trigeminal Neuralgia: A Multicenter, Randomized, Of 31 participants screened, 22 were randomized; 1 placebo-assigned participant did not meet the NRS ≥5 criterion and was excluded, leaving 21 for analysis (IFT: 11; placebo: 10). Neurology • 2026-06-09 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42096672 ↗ |
| New Insights on AVOID; a phase III, randomised controlled trial using indocyanine green for the: What a 978-Participant Study Found This protocol has been approved by the Medical Ethical Committee Leiden-Den Haag-Delft (METC-LDD) and is registered at ClinicalTrials.gov and trialregister.nl. BMJ open • 2022-04-01 • Phase III Randomized Trial | N = 978 | 87/100 | PMID 35365509 ↗ |
| Plant Protein vs. Whey: Which One Actually Builds Muscle Better? Soy- and pea-based protein supplements may support favorable muscle and body-fat improvements in adults strength training and could be considered practical nutritional options for individuals seeking alternatives to whey protein. Journal of the International Society of Sports Nutrition • 2026-12-30 • Meta-Analysis | Multi-cohort | 86/100 | PMID 42954267 ↗ |
| Can This Approach Help? Inside the Latest Research on Dosimetric Evaluation of Organs at Risk From SAVE Experimental short-course VCB of 11 Gy × 2 fx to the surface provides a comparable biologically effective dose to SOC courses. International journal of radiation oncology, biology, physics • 2023-09-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37023988 ↗ |
Phenytoin toxicity Patient Community & “People Like Me” Threads
Filter Phenytoin toxicity community threads and patient logs by age, biological sex, dosage, and treatment duration.